Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study
In this real-world study of patients with epithelial ovarian cancer receiving first-line maintenance niraparib monotherapy, drug toxicity was the most common reason for treatment discontinuation in early discontinuers. Effective and early clinical management of drug toxicity may help mitigate these adverse events, allowing patients to remain on niraparib maintenance treatment longer and experience the potential full therapeutic benefit.
Authors
- John D. Hartman (ORCID: https://orcid.org/0000-0002-8310-2373)
- Floor Jenniskens Backes (ORCID: https://orcid.org/0000-0002-9225-6913)
- Jessica Perhanidis (ORCID: https://orcid.org/0000-0001-6943-8500)
- Jean Hurteau
- Tirza Areli Calderón Boyle
- Jeanne M. Schilder (ORCID: https://orcid.org/0000-0002-6322-5376)
- Jonathan T. Lim (ORCID: https://orcid.org/0009-0007-9139-8841)
- Ritu Salani (ORCID: https://orcid.org/0000-0002-5646-343X)
- Amanda Golembesky
Institutions
- University of California, Los Angeles (US)
- Providence College (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- GlaxoSmithKline (United States) (US)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1016/j.ijgc.2024.100044
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- GlaxoSmithKline